Skip to content

Noninvasive Blood Glucose Monitoring Using Otoacoustic Emissions

Noninvasive Blood Glucose Monitoring Using Otoacoustic Emissions

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01073137
Enrollment
44
Registered
2010-02-23
Start date
2006-06-30
Completion date
2010-06-30
Last updated
2010-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Keywords

diabetes

Brief summary

The purpose of the research is to determine whether a noninvasive hearing test may be used to predict blood glucose in people with diabetes.

Detailed description

Participation in the study will involve listening to sounds through earphones while blood glucose levels are measured by taking blood samples using a lancet. During the study, blood glucose levels will be increased by drinking a beverage containing sugar. Up to five visits to the NCRAR will be needed over a six-month period to complete the study. Each visit lasts either two or four hours, and will be scheduled at your convenience. You will be paid $20 for the first 2-hour screening visit and $50 for each 4-hour visit. You will be paid $30 if you are selected to participate in a 2-hour Attention Correlation Test that a sub-set of 10 participants will complete.

Interventions

None listed

Sponsors

Portland VA Medical Center
Lead SponsorFED

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older * Diabetes * Normal hearing * Hemoglobin A1C of 5.5-8%

Exclusion criteria

* Volunteers may not participate if they have peripheral neuropathy * visual impairment due to diabetic retinopathy * organ failure (kidney, liver heart, or lungs) * severe or unstable cardiovascular disease * active alcohol or drug abuse * schizophrenia * bipolar disorder * active major depressive disorder * active foot ulcerations * active viral or other infections such as HIV * hepatitis, or pneumonia * serious renal * cardiac or cognitive dysfunction.

Design outcomes

Primary

MeasureTime frame
Otoacoustic emissions change with blood sugar levelsOne 2-hour screening visit, and on 4-hour visit

Countries

United States

Contacts

Primary ContactPeter G Jacobs, MSEE
Peter.Jacobs@va.gov503-220-8262

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026